
Aurora Cannabis ACB
$ 3.48
1.16%
Annual report 2025
added 04-25-2026
Aurora Cannabis Total Assets 2011-2026 | ACB
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Aurora Cannabis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 853 M | 862 M | 926 M | 1.08 B | 2.6 B | 2.78 B | 5.5 B | 1.89 B | 323 M | 18.4 M | 13.5 M | 1.89 M | 719 K | 1.12 M | 1.39 M |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.5 B | 719 K | 1.12 B |
Quarterly Total Assets Aurora Cannabis
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 2.6 B | - | - | - | 2.78 B | - | - | - | 5.5 B | - | - | - | 1.89 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.5 B | 1.89 B | 3.19 B |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | ||
|
Cronos Group
CRON
|
1.93 B | $ 2.64 | -1.12 % | $ 1.36 B | ||
|
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M | ||
|
Harrow Health
HROW
|
399 M | $ 40.9 | 0.91 % | $ 1.5 B | ||
|
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | ||
|
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 4.36 | 4.06 % | $ 61.3 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
41 M | - | - | $ 33.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | ||
|
Pacira BioSciences
PCRX
|
1.55 B | $ 24.44 | -4.12 % | $ 1.13 B | ||
|
Solid Biosciences
SLDB
|
233 M | $ 7.13 | -1.79 % | $ 624 M | ||
|
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | ||
|
Bausch Health Companies
BHC
|
27.4 B | $ 5.65 | -1.22 % | $ 2.06 B | ||
|
Canopy Growth Corporation
CGC
|
918 M | $ 1.13 | 1.8 % | $ 122 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 1.2 | 9.09 % | $ 1.49 M | ||
|
Tilray
TLRY
|
4.31 B | $ 6.16 | -1.28 % | $ 3.81 B | ||
|
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
408 M | $ 1.42 | 0.71 % | $ 402 M | ||
|
Veru
VERU
|
60.4 M | $ 2.26 | 0.44 % | $ 305 M | ||
|
Evolus
EOLS
|
226 M | $ 5.33 | -1.11 % | $ 344 M | ||
|
Sundial Growers
SNDL
|
1.34 B | $ 1.41 | 3.68 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
1.82 B | $ 8.47 | 2.67 % | $ 434 M | ||
|
Organogenesis Holdings
ORGO
|
498 M | $ 2.57 | 9.36 % | $ 338 M | ||
|
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
10.6 M | $ 0.87 | 0.14 % | $ 3.75 M | ||
|
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | ||
|
Assertio Holdings
ASRT
|
267 M | $ 18.47 | 0.22 % | $ 118 M | ||
|
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
94 M | $ 7.64 | 1.6 % | $ 302 M | ||
|
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
59 M | $ 0.99 | 6.48 % | $ 49.4 M | ||
|
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
50 B | $ 15.04 | 0.67 % | $ 18.1 B | ||
|
Zomedica Corp.
ZOM
|
127 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
57.1 M | $ 0.89 | 1.29 % | $ 32 M | ||
|
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
31 M | $ 0.53 | -2.39 % | $ 2.27 M | ||
|
TherapeuticsMD
TXMD
|
37.7 M | $ 2.07 | 1.47 % | $ 23.9 M |